Transition Therapeutics Inc.
415 Yonge Street
Suite 1103
Toronto
Ontario
M5B2E7
Canada
Tel: 416-260-7770
Fax: 416-260-2886
183 articles about Transition Therapeutics Inc.
-
Transition Therapeutics Inc. to Hold Conference Call on Full Year Fiscal 2012 Financial Results on Thursday, September 13th, at 4:30 P.M. EST
9/12/2012
-
Transition Therapeutics Inc. Announces Dosing of First Patient in Phase 2 Clinical Study of ELND005 in Bipolar Disorder
8/30/2012
-
Transition Therapeutics Inc. to Present at the Canaccord Genuity Annual Growth Conference
8/14/2012
-
Transition Therapeutics Inc. Announces Results of Phase 1 Clinical Study of TT-401
6/18/2012
-
Transition Therapeutics Inc. Announces ELND005 Presentations at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies
5/14/2012
-
Transition Therapeutics Inc. Announces Third Quarter Fiscal 2012 Financial Results
5/9/2012
-
Transition Therapeutics Inc. to Hold Conference Call on Third Quarter Fiscal 2012 Financial Results on Tuesday, May 8th, at 4:30 P.M. EDTtra
5/7/2012
-
Transition Therapeutics Inc. Announces ELND-005 Presentations at the American Academy of Neurology Meeting
4/26/2012
-
Transition Therapeutics Inc. Announces Second Quarter Fiscal 2012 Financial Results
2/10/2012
-
Transition Therapeutics Inc. to Hold Conference Call on Second Quarter Fiscal 2012 Financial Results on Thursday, February 9th, at 4:30 P.M. EST
2/7/2012
-
Transition Therapeutics Inc. Appoints New Chief Financial Officer
12/12/2011
-
Transition Therapeutics Inc. Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401
12/12/2011
-
Transition Therapeutics Inc. Announces the Departure of Its President and Chief Financial Officer
12/9/2011
-
Transition Therapeutics Inc. Announces First Quarter Fiscal 2012 Financial Results
12/2/2011
-
Transition Therapeutics Inc. Completes US $5 Million Private Placement
11/23/2011
-
Transition Therapeutics Inc. Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
9/27/2011
-
Transition Therapeutics Inc. Announces Fiscal 2011 Year End Financial Results
9/20/2011
-
Transition Therapeutics Inc. to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
9/19/2011
-
Transition Therapeutics Inc. to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
9/9/2011
-
Transition Therapeutics Inc. Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
7/18/2011